A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients with Inhibitors

Phase 1

• Conditions: Haemophilia A with inhibitors Haemophilia B with inhibitors; MedDRA version: 20.0 Level: LLT Classification code 10053751 Term: Hemophilia A with anti factor VIII System Organ Class: 100000004850; MedDRA version: 20.0 Level: LLT Classification code 10053752 Term: Hemophilia B with anti factor IX System Organ Class: 100000004850; Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]

• Registration Number: EUCTR2016-000510-30-DK
• Lead Sponsor: ovo Nordisk A/S

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-06-04
• Last Update Posted: 11 March 2020

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Not specified
• Target Recruitment: 26

Inclusion Criteria

- Informed consent obtained before any trial related activities. Trial related activities are any procedures that are carried out as part of the trial, including activities to determine the suitability for the trial
- Male haemophilia A or B patients with inhibitors aged 18 years or older at the time of signing informed consent
- Patients currently in need of treatment with bypassing agents
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 24
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 2

Exclusion Criteria

- Known or suspected hypersensitivity to trial product(s) or related products
- Known inherited or acquired bleeding disorder other than haemophilia
- Ongoing or planned immune tolerance induction therapy or prophylaxis with FVIII or FIX

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: To assess the efficacy of concizumab administered s.c. once daily in preventing bleeding episodes in haemophilia A and B patients with inhibitors;<br> Secondary Objective: 1. To assess the longer-term efficacy of concizumab in haemophilia patients with inhibitors<br> 2. To assess the safety of concizumab in haemophilia patients with inhibitors<br> 3. To assess the safety of administering recombinant factor VIIa (rFVIIa) to haemophilia patients with inhibitors that are exposed to concizumab<br> 4. To assess the immunogenicity of concizumab in haemophilia patients with inhibitors<br> ;Primary end point(s): The number of bleeding episodes;Timepoint(s) of evaluation of this end point: During at least 24 weeks from treatment onset

Secondary Outcome Measures

Name	Time	Method
<br> Secondary end point(s): 1. The number of spontaneous bleeding episodes<br> 2. Number of treatment emergent adverse events (TEAEs)<br> ;<br> Timepoint(s) of evaluation of this end point: 1.+ 2. During at least 24 weeks from treatment onset<br><br>